|
Canada-0-LaboratoriesTesting ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
With our recently reported platform validation we are entering a new chapter in CureVac’s development, which marks a natural transition for me CureVac is stronger than ever as I hand over to Alexander Zehnder His expertise will add a lot to shape the future success of CureVac ”
- CureVac - Wikipedia
On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by the company founder Ingmar Hoerr
- BioNTech Announces Strategic Transaction to Acquire CureVac in Public . . .
“To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a disruptive technology to develop transformative therapies with greater scale and speed,” said Dr Alexander Zehnder, CEO of CureVac
- A New Chapter Begins Today marks a truly exciting and . . . - LinkedIn
Alexander Zehnder, MD, MBA Zehnder, CEO of CureVac: “To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a
- CureVac appoints new CEO - bionity. com
CureVac N V announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr Franz Haas will step down as CEO, effective March 31, 2023 Dr Alexander Zehnder will succeed Dr Haas, joining from Sanofi on April 1, 2023
- Alexander Zehnder - CEO at CureVac | The Org
Alexander Zehnder, MD, MBA, currently serves as the Chief Executive Officer of CureVac since April 2023
- CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes
- CureVac Management
Dr Alexander Zehnder, M D, MBA, is Chief Executive Officer at CureVac N V since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023
- CureVac N. V. . (1 10 23). Press Release: CureVac Appoints Alexander . . .
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes
- Who is the CEO of CureVac (CVAC)? - financecharts. com
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA) The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees
|
|